Table 1.
US FDA-approved oncology drugs with package inserts containing pharmacogenetics and pharmacogenomics information.
| Drug | Pharmacogenomic biomarker(s) |
|---|---|
| Ado-trastuzumab emtansine | ERBB2 |
| Afatinib | EGFR |
| Anastrozole | ESR1, PGR |
| Arsenic trioxide | PML/RARA |
| Bosutinib | BCR/ABL1 |
| Brentuximab vedotin | TNFRSF8 |
| Busulfan | Ph chromosome |
| Capecitabine | DPYD |
| Cetuximab | EGFR, KRAS |
| Cisplatin | TPMT |
| Crizotinib | ALK |
| Dabrafenib | BRAF, G6PD |
| Dasatinib | BCR/ABL1 |
| Denileukin diftitox | IL2RA |
| Erlotinib | EGFR |
| Everolimus | ERBB2, ESR1 |
| Exemestane | ESR1 |
| Fluorouracil | DPYD |
| Fulvestrant | ESR1 |
| Ibritumomab tiuxetan | MS4A1 |
| Imatinib | KIT, BCR/ABL1, PDGFRB, FIP1L1/PDGFRA |
| Irinotecan | UGT1A1 |
| Lapatinib | ERBB2 |
| Letrozole | ESR1, PGR |
| Mercaptopurine | TPMT |
| Nilotinib | BCR/ABL1, UGT1A1 |
| Obinutuzumab | MS4A1 |
| Ofatumumab | MS4A1 |
| Omacetaxine | BCR/ABL1 |
| Panitumumab | EGFR, KRAS |
| Pazopanib | UGT1A1 |
| Pertuzumab | ERBB2 |
| Ponatinib | BCR-ABL T315I |
| Rasburicase | G6PD |
| Rituximab | MS4A1 |
| Tamoxifen | ESR1, PGR, F5, F2 |
| Thioguanine | TPMT |
| Tositumomab | MS4A1 |
| Trametinib | BRAF |
| Trastuzumab | ERBB2 |
| Tretinoin | PML/RARA |
| Vemurafenib | BRAF |
F2: Prothrombin; F5: Factor V Leiden; Ph: Philadelphia.
Data taken from [32].